The global tumor ablation market size is expected to reach USD 4.17 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.3% during the forecast period (2024 – 2032).
The tumor ablation market is a rapidly growing segment within the global oncology therapeutics space. Tumor ablation refers to a minimally invasive procedure that uses various techniques to destroy or shrink tumors, particularly for those that are difficult to treat through traditional surgical methods. Ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser ablation, are used for treating solid tumors in organs like the liver, lungs, kidneys, and bones.
Market Growth Drivers
- Rising Incidence of Cancer: The global rise in cancer cases, driven by aging populations, lifestyle factors, and genetic predispositions, is a primary factor fueling the demand for tumor treatment options, including ablation therapies.
- Technological Advancements: Innovations in ablation technologies, such as improved imaging systems, precision instruments, and energy sources, are enhancing the effectiveness of tumor ablation procedures and making them more widely applicable for various types of tumors.
- Minimally Invasive Treatment Demand: As healthcare shifts toward minimally invasive and less invasive therapies, patients and healthcare providers are increasingly opting for tumor ablation over traditional surgical approaches due to the shorter recovery times and fewer complications.
Download Free Sample PDF Copy of the Report:
Key Companies in the Tumor Ablation Market Include:
- AngioDynamics Inc.
- Boston Scientific Corp.
- BVM Medical Ltd.
- BTG International Ltd.
- EDAP TMS S.A.
- Integra LifeSciences Holdings Corp.
Key Trends in the Tumor Ablation Market
- Integration of Image-Guided Techniques: Real-time imaging techniques, such as CT, MRI, and ultrasound, are increasingly integrated into tumor ablation procedures. This allows for precise targeting and monitoring of tumor tissue, improving treatment outcomes and reducing the risk of damage to surrounding healthy tissues.
- Combination Therapies: Tumor ablation is increasingly being used in combination with other cancer treatments, such as chemotherapy, immunotherapy, and radiation, to enhance treatment effectiveness and improve patient outcomes.
- Personalized Medicine: The growing emphasis on personalized medicine is driving the development of more tailored and patient-specific ablation techniques based on the tumor’s type, location, and genetic profile.
Research Scope
- Technological Innovations: Ongoing research into new and improved energy sources, imaging techniques, and ablation devices is central to expanding the market’s capabilities and improving the efficacy of treatments.
- Clinical Efficacy and Safety: Studies focusing on the long-term effectiveness, recurrence rates, and safety profiles of tumor ablation therapies compared to traditional treatments are critical for validating and optimizing these procedures.
- Combination Therapies: Investigating the synergistic effects of combining tumor ablation with other cancer therapies, such as targeted therapies, immunotherapy, and systemic treatments, is a growing area of interest in clinical trials.
Market Segmentation
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Tumor Ablation Market, Mode of Treatment Outlook (Revenue – USD Billion, 2019-2032)
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
Tumor Ablation Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Bone Metastasis
- Bone Metastasis
Tumor Ablation Market, Technology Outlook (Revenue – USD Billion, 2019-2032)
- Radiofrequency (RF) Ablation
- Microwave Ablation
- Cryoablation
- Others
Tumor Ablation Industry Developments
April 2023: Compal Electronics launched a radiofrequency ablation (RFA) system designed for both percutaneous and intraoperative coagulation, as well as soft tissue ablation. The system offers enhanced precision for tumor treatment and is part of the company’s growing portfolio in the medical device sector. In addition, Compal introduced a bilevel ventilator aimed at managing chronic obstructive pulmonary disease (COPD) and respiratory insufficiency resulting from central and mixed apneas.
March 2023: AngioDynamics entered into a strategic partnership with Minimax Medical to expand the global distribution of its product portfolio. This collaboration includes the international distribution of Minimax’s advanced Radiofrequency Ablation System, designed for the treatment of tumors and nodules, further extending AngioDynamics’ reach in the oncology space.
February 2024: AngioDynamics and Immunophotonics announced a collaborative partnership focused on combining immunotherapy with ablation techniques for solid tumor cancers. The partnership leverages Immunophotonics’ IP-001 along with AngioDynamics’ ablation devices to explore the synergistic effects of these therapies, aiming to enhance the efficacy of cancer treatments through innovative combination strategies.
Technical advancements, mainly in robotics-assisted tumor ablation techniques, are a significant driver in the tumor ablation market. Robotics systems, accomplished with navigation capabilities and advanced imaging, facilitate surgeons to diminish cancer tissues and accurately target with less damage to the healthy cells.